ClinicalTrials.gg
CompletedNCT00307632Updated May 15, 2014

An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol

A Phase 4 interventional study of Norelgestromine (NLGM)/ethinyl estradiol (EE) in Contraception, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 12 sites in 2 countries. Open to female participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-15.

Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
580
Allocation
Non-randomized
Ages
21 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal contraceptive system, norelgestromine and ethinyl estradiol (NLGM / EE).

Read the detailed description

A multicenter, open label, descriptive study. Five hundred requiring contraception will receive the weekly transdermal contraceptive patch for 6 cycles. At the baseline and after the 1st, 3rd and 6th cycles, satisfaction with the method will be assessed. The contraceptive efficacy will be assessed by the Pearl Index and by life table analysis. To assess satisfaction with the weekly transdermal contraceptive patch, this method will be compared to the previous contraceptive method. Adhesion, cycle control, safety and efficacy are secondary outcomes. Treatment duration: 6 cycles (4 weeks each). The subject will wear a 20 cm2 contraceptive transdermal patch for one full week, apply a fresh patch for week 2, and a third patch for week 3. The fourth week will be patch-free. Each patch deliveries 150 mcg of NLGM and 20 mcg of EE per day.

02

Conditions studied

  • Contraception

Keywords

  • Contraception
  • Hormonal patch
  • Norelgestromine
  • Ethinyl estradiol
03

In context

Lead sponsor

Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult females who meet the following selection criteria: Have regular menses occuring every 25-35 days
  • Acceptable body mass (\< 30) and the weight is \< 90 kg
  • Has completed her last term pregnancy at least 4 months prior to study admission, is not lactating and has at least one normal menstrual period since her last pregnancy and not breast feeding
  • Has a sitting blood pressure systolic \< 140 mm/Hg and diastolic \< 90 mm/Hg.

Exclusion criteria

Exclusion Criteria:

  • Has not received a DepoProvera injection or any other depot hormone injection within six months prior to the screening visit
  • Has not used / or in current use of barbiturates, antiepileptics, rifampin, griseofulvin, Hypericum perforatum, or other hepatic enzyme-inducing drugs within 30 days prior to the pre-study visit
  • Has not a uncontrolled disorder
  • No women over the age 35 who smoke.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Norelgestromine (NLGM)/Ethinyl Estradiol (EE)

    Drug: Norelgestromine (NLGM)/ethinyl estradiol (EE)

Interventions

  • DrugNorelgestromine (NLGM)/ethinyl estradiol (EE)

    Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).

06

What researchers measure

Primary outcomes

  1. Pregnancy Rate Determined by Pearl Index

    Pearl Index is the number of pregnancies with use of therapy divided by the number of cycles with therapy use. It is an estimation of the number of pregnancies per 100 woman-years of product use.

    Time frame: Cycle 6 (Day 168)

  2. Pregnancy Rate Determined by Table of Life Analysis

    Pregnancy rate was determined by table of life analysis.

    Time frame: Cycle 6 (Day 168)

Secondary outcomes

  1. Percentage of Participants With Breakthrough Bleeding and/or Spotting

    Percentage of participants with breakthrough bleeding and/or spotting was reported.

    Time frame: Day 28 of Cycle 1, 3 and 6

  2. Compliance Score

    Score of compliance was calculated for each participant by dividing the number of cycles with at least one day without the study drug by the total number of therapy cycles. Average score was calculated for cycle 1 to 6.

    Time frame: Day 28 of Cycle 1, 2, 3, 4, 5 and 6

  3. Percentage of Participants With Response to Satisfaction Questionnaire

    Percentage of participants with response to satisfaction questionnaire was reported for following categories: previous contraceptive, method election, physical well-being, emotional well-being, intermenstrual bleeding and intensity, menstrual flow volume, pre-menstrual symptoms, and easiness in ethinyl estradiol and norelgestromin transdermal patch use.

    Time frame: Day 28 of Cycle 1, 3 and 6

07

Study locations

12 sites
  • Belo Horizonte, Brazil
  • Botucatu, Brazil
  • Brasilia, Brazil
  • Curitiba, Brazil
  • Goiânia, Brazil
  • Porto Alegre, Brazil
  • Ribeirao Preto, Brazil
  • Sao Paulo, Brazil
  • Sorocaba, Brazil
  • Ciudad De Mexico, Mexico
  • Mexico, Mexico
  • Monterrey, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2006
First posted
Mar 28, 2006
Start
Feb 2003
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Last update
May 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00307632
Responsible party
Sponsor
First posted
Mar 28, 2006
Start date
Feb 2003
Primary completion
Dec 2004
Completion
Dec 2004
Last update
May 15, 2014

Study contacts

Janssen-Cilag Farmaceutica Ltda. Clinical Trial
study director · Janssen-Cilag Farmaceutica Ltda.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion